Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.
about
Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibitionProtein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteinsWhither or wither microbicides?Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans.Polyanions--a lost chance in the fight against HIV and other virus diseases?Enhancement of HIV infection by cellulose sulfate.A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats.Surrogacy in antiviral drug development.Hybridization-based detection of Helicobacter pylori at human body temperature using advanced locked nucleic acid (LNA) probes.Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compoundsSulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens.Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Antiviral therapy for human immunodeficiency virus infectionsHIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcriptionMixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studiesTherapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors.Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation.Recent advances in anti-HIV natural products.Polymeric anti-HIV therapeutics.Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds.Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models.Sulfated fibroin, a novel sulfated peptide derived from silk, inhibits human immunodeficiency virus replication in vitro.Inducing single-cell suspension of BTI-TN5B1-4 insect cells: II. The effect of sulfated polyanions on baculovirus infection.FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes.Pharmacologic considerations for antiviral drug development.Low molecular weight dextran sulfate binds to human myoblasts and improves their survival after transplantation in mice.The metabolic fate of the Anti-HIV active drug carrier succinylated human serum albumin after intravenous administration in rats.Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models.Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation.Traditional medicines, HIV, and related infections: workshop 2C.Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS.Macromolecular (pro)drugs in antiviral research
P2860
Q27004059-F63FA493-8483-4AB9-BC71-2D3C330F9CA2Q28369377-6B270DD3-0A28-4D0C-8511-87777DDBC3D0Q33715907-F58248B1-B621-48FF-901B-E7DD76CF3C9CQ33797964-8FD000D5-AC43-43D0-AC86-063185CD862FQ33889449-4A5DF6D1-746A-4414-B253-DD8CEC84417BQ33907686-7D97CD2E-5803-4FF1-898E-53DCB7877F2FQ34009817-3CD48734-BAD8-4084-9FA7-134AD49C5251Q34080823-B737A706-5874-45B1-B655-C11CE827684DQ34293761-1D54DA36-DCDC-4CCB-9C62-36C1D4AA4631Q34722747-E2AA6BF0-14D8-4645-8FE1-FA42C8F214C4Q35053931-C33B965A-CAA1-4A09-8A0D-39A26C2B2BBFQ35122064-EB0C085A-DE24-4AEF-AAAB-CD9DAEA1ED84Q35123273-C16049F8-DEDC-421D-9337-A06168F00C7CQ35139547-619D16D8-CC58-485B-9526-C2BA3FEFC97AQ35175233-A236C3BE-EC1C-4115-A8FC-D71542917BEFQ35325810-B993BCCF-DA97-45CD-B6D7-0EED2806E548Q35366050-3D164717-9304-4BA8-A3FF-666FC5F31677Q35612098-15B42203-457A-408A-972E-89DFFFF6077EQ36052460-FD2B3282-2D6E-4DA4-AA33-79B8A31A7F2DQ36181360-4A7307B8-5E17-4F88-9FFE-9CD49AFB7DA1Q37088591-E6127C8E-A44E-4534-BEA0-C4762A1224DCQ37201370-617AC77E-63B4-475A-B529-983A69416588Q37278750-4B2D8D00-D2BB-43E8-858F-BB53F471C7B2Q37803138-B6157274-3E2B-4E40-9B4D-BB7FC0E9C4DCQ38245819-A9891BC5-4ECD-400B-94BD-061761BDC4BDQ39248702-AE72195A-D36B-4C0C-80BD-B508C32EA36AQ39885075-C08A9F51-B7D1-4669-ADBC-B3832B938C96Q40826284-36DD9192-E7F7-42AE-AA9B-CD942428DF64Q40854583-04E0EE8F-3AA3-4F88-B0E7-B7BB4FB08594Q41110816-8F684843-CD66-4FE7-AEEF-8595D1277996Q41119643-92C62D5B-79F6-4E53-AE6C-23E6EFE1547EQ41172065-67505CEC-A728-41C3-AD64-D622E9022734Q43419500-57AD5AE0-EE05-4BFD-9F77-E1A5271E7853Q43791104-DBDBD48E-3C5B-4BB7-A974-E88174214F67Q44852485-D6F0972A-BEC1-426E-9FED-F4CD40012283Q46903624-CF490D26-729B-46EC-A27C-2FE8B2F1947EQ47310550-CD31C71D-4113-4FC5-BFA7-BA3CCBD5E04BQ47340027-46D61453-E4E6-464B-BF79-8BA315477D5FQ57376798-F0097621-0FA0-4381-BE25-2A2D6B0E7CE7
P2860
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.
description
1991 nî lūn-bûn
@nan
1991 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@ast
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@en
type
label
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@ast
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@en
prefLabel
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@ast
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@en
P2093
P2860
P356
P1476
Pharmacokinetics, toxicity, an ...... unodeficiency virus infection.
@en
P2093
C W Hendrix
D M Kornhauser
H Farzadegan
K J Lorentsen
L J Nerhood
P A Barditch-Crovo
R E Chaisson
P2860
P304
P356
10.1128/AAC.35.12.2544
P407
P577
1991-12-01T00:00:00Z